Edesa Biotech (EDSA) Profit After Tax (2013 - 2026)

Edesa Biotech has reported Profit After Tax for 13 years, with the latest figure at -$2.3 million in Q4 2025.

• Quarterly Profit After Tax fell 39.31% year-over-year to -$2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.0 million (down 31.26% YoY) and the FY2025 annual result came in at -$7.2 million, down 15.93% from the prior year.
• Profit After Tax advanced to -$2.3 million in Q4 2025 per EDSA's latest filing, from -$2.4 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$979873.0 in Q3 2024 and troughed at -$5.8 million in Q2 2022.
• A 5-year average of -$2.6 million and a median of -$2.3 million in 2021 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2021 and 2023: Profit After Tax sank 170.24% in 2021, then surged 66.19% in 2023.
• Over 5 years, Profit After Tax stood at -$4.3 million in 2021, then soared by 46.29% to -$2.3 million in 2022, then advanced by 28.09% to -$1.7 million in 2023, then gained by 3.68% to -$1.6 million in 2024, then sank by 39.31% to -$2.3 million in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.3 million, -$2.4 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.